(MedPage Today) — PHILADELPHIA — For multi-allergen oral immunotherapy (mOIT) patients, adding dupilumab (Dupixent) after omalizumab (Xolair) showed promise for cutting the gastrointestinal adverse events (AE) of ongoing mOIT, although perhaps…
Source link : https://www.medpagetoday.com/meetingcoverage/aaaai/120098
Author :
Publish date : 2026-02-28 21:37:00
Copyright for syndicated content belongs to the linked Source.
